Rapirosiran
Rapirosiran is a N-acetylgalactosamine-conjugated small-interfering RNA targeting liver-expressed hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13) mRNA. Loss-of-function variants in the HSD17B13 associated with reduced risk of chronic liver disease. Rapirosiran can be used for the study of Non-alcoholic steatohepatitis.
Product Specifications
CAS Number
2755196-97-3
Product Name Alternative
ALN-HSD; ALN-288996; AD-288996
UNSPSC
12352211
Target
17β-HSD
Related Pathways
Metabolic Enzyme/Protease
Field of Research
Metabolic Disease
Smiles
[Rapirosiran]
Molecular Formula
C530H719F7N171O323P43S6
Molecular Weight
16307.22
References & Citations
[1]Sanyal AJ, Taubel J, Badri P, et al. Phase I randomized double-blind study of an RNA interference therapeutic targeting HSD17B13 for metabolic dysfunction-associated steatohepatitis. J Hepatol. 2025;83 (4) :838-848.
Shipping Conditions
Room temperature
Scientific Category
Oligonucleotides
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC041037-100 1x 100 µL
CD44 Standard (DF1485), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC040040-500 1x 500 µL
CD35 / CR1 (E11), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC942216-100 1x 100 µL
CD50 / ICAM3 (CG106), CF594 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC140017-500 1x 500 µL
Ep-CAM / CD326 (VU-1D9), CF514 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC470009-500 1x 500 µL
MART-1 / Melan-A (M2-7C10), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details